Comparative Efficacy of Biologic Therapies for Psoriasis: Insights from Head-to-Head Studies
International Journal of Molecular Sciences · 18.11.2026 · 27 (22) · 10376
DOI: 10.3390/ijms272210376 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.11.2026. Verfasst von Adam Rafałowicz und 2 weiteren Autor:innen. Die Arbeit nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Biologic therapies have substantially transformed the management of moderate-to-severe psoriasis, but differences in efficacy, speed of response, durability, and safety reflect the distinct immunological pathways targeted by individual agents. The aim of this review is the analysis and comparison of particular biological agents in terms of efficacy and safety. Head-to-head trials consistently demonstrate that IL-17 and IL-23 inhibitors achieve greater skin clearance than first-generation TNF-α inhibitors. IL-17 blockade, particularly with agents targeting IL-17A, produces rapid clinical improvement by directly suppressing keratinocyte-driven inflammation. Dual IL-17A/IL-17F inhibition with bimekizumab may provide even greater clearance, although broader IL-17 inhibition is associated with a higher frequency of mucosal candidiasis. In contrast, selective IL-23 inhibition acts upstream by suppressing the differentiation and maintenance of pathogenic Th17 cells and appears to provide particularly durable disease control. Selective IL-23 inhibitors may also preserve potentially protective IL-12 signaling, distinguishing them from ustekinumab, which targets the shared p40 subunit. Safety profiles are generally favorable across biologic classes, although mechanism-specific risks include tuberculosis reactivation with TNF-α inhibitors, candidiasis with IL-17 inhibitors, and inflammatory bowel disease concerns with IL-17 blockade. Therefore, biologic selection should be individualized according to disease severity, required speed and durability of response, comorbidities, affected anatomical sites, safety considerations, dosing frequency, patient preferences and adherence goals. Current comparative evidence supports increasingly targeted approaches within the IL-23/IL-17 axis.
Zitieren
APA
Rafałowicz, A., Nowowiejska-Purpurowicz, J., & Flisiak, I. (2026). Comparative Efficacy of Biologic Therapies for Psoriasis: Insights from Head-to-Head Studies. International Journal of Molecular Sciences, 27(22), 10376. https://doi.org/10.3390/ijms272210376
Vancouver
Rafałowicz A, Nowowiejska-Purpurowicz J, Flisiak I. Comparative Efficacy of Biologic Therapies for Psoriasis: Insights from Head-to-Head Studies. International Journal of Molecular Sciences. 2026;27(22):10376. doi:10.3390/ijms272210376
BibTeX
@article{Rafaowicz2026,
author = {Rafałowicz, Adam and Nowowiejska-Purpurowicz, Julia and Flisiak, Iwona},
title = {Comparative Efficacy of Biologic Therapies for Psoriasis: Insights from Head-to-Head Studies},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {22},
pages = {10376},
doi = {10.3390/ijms272210376}
}
EUVIMED